These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28885612)

  • 41. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects.
    Morelli F; Matis S; Benelli R; Salvini L; Zocchi MR; Poggi A
    Cells; 2024 May; 13(10):. PubMed ID: 38786084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brentuximab vedotin for treatment of systemic T-cell lymphoma.
    Chihara D; Oki Y
    Expert Opin Biol Ther; 2014 Oct; 14(10):1519-26. PubMed ID: 25200691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brentuximab vedotin.
    Ansell SM
    Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
    J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies.
    Schwarting R; Behling E; Allen A; Arguello-Guerra V; Budak-Alpdogan T
    Arch Pathol Lab Med; 2022 Apr; 146(4):415-432. PubMed ID: 35299246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
    Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
    Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    Perrot A; Monjanel H; Bouabdallah R; Quittet P; Sarkozy C; Bernard M; Stamatoullas A; Borel C; Bouabdallah K; Nicolas-Virelizier E; Fournier M; Morschhauser F; Brice P;
    Haematologica; 2016 Apr; 101(4):466-73. PubMed ID: 26768687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
    Garnock-Jones KP
    Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
    Bradley AM; Devine M; DeRemer D
    Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
    Carbone A; Gloghini A; Volpe R
    Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of CD30 as a biomarker to predict response to brentuximab vedotin.
    Xu ML; Acevedo-Gadea C; Seropian S; Katz SG
    Histopathology; 2016 Jul; 69(1):155-8. PubMed ID: 26648051
    [No Abstract]   [Full Text] [Related]  

  • 56. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
    Chen X; Soma LA; Fromm JR
    Onco Targets Ther; 2013 Dec; 7():45-56. PubMed ID: 24379682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Pierce JM; Mehta A
    Expert Rev Hematol; 2017 Jan; 10(1):29-37. PubMed ID: 27927047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brentuximab vedotin (replased/refractory Hodgkin lymphoma and CD30 positive non-Hodgkin lymphoma.
    Kitahara H
    Gan To Kagaku Ryoho; 2015 May; 42(5):550-2. PubMed ID: 26054088
    [No Abstract]   [Full Text] [Related]  

  • 60. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin.
    Cao ZG; Zhou HW; Peng CJ; Liu M; Du Y; Yang QM
    Chin J Cancer; 2013 Sep; 32(9):520-3. PubMed ID: 23544448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.